Internal body clock controls fat metabolism

ScienceDaily (Nov. 15, 2010) ? UC Irvine researchers have discovered that circadian rhythms -- the internal body clock -- regulate fat metabolism. This helps explain why people burn fat more efficiently at certain times of day and could lead to new pharmaceuticals for obesity, diabetes and energy-related illnesses.

The study was headed by Paolo Sassone-Corsi, Donald Bren Professor and chair of pharmacology. A leading expert on circadian rhythms, he discovered many of the key molecular switches governing these biological processes. He and his colleagues found that one of these, a protein called PER2, directly controls PPAR-gamma, a protein essential for lipid metabolism. Since circadian proteins are activated by 24-hour, light-dark patterns, PER2 turns on and off PPAR-gamma's metabolic capabilities at regular intervals.

"What surprised us most, though, is that PER2 targets one specific amino acid on the surface of the PPAR-gamma molecule," Sassone-Corsi said. "This kind of specificity is very rare in cell biology, which makes it exciting, because it presents us with a singular target for drug development."

Daniele Piomelli, Louise Turner Arnold Chair in Neurosciences at UCI, and Todd Leff, associate professor of pathology at Wayne State University in Detroit, collaborated on the study, which appears this month in Cell Metabolism.

Twenty-four-hour circadian rhythms regulate fundamental biological and physiological processes in almost all organisms. They anticipate environmental changes and adapt certain bodily functions to the appropriate time of day. Disruption of these cycles can profoundly influence human health and has been linked to obesity, diabetes, insomnia, depression, heart disease and cancer.

Last year, Sassone-Corsi helped discover that proteins involved with circadian rhythms and metabolism are intrinsically linked and dependent upon each other to ensure that cells operate properly and remain healthy.

Rajesh H. Amin and James G. Granneman of Wayne State University and UCI's Benedetto Grimaldi, Marina Maria Bellet, Sayako Katada, Giuseppe Astarita and Jun Hirayama contributed to the current study, supported by the National Institutes of Health.

Editor's Note: This article is not intended to provide medical advice, diagnosis or treatment.

Story Source:

The above story is reprinted (with editorial adaptations by ScienceDaily staff) from materials provided by University of California - Irvine.

Journal Reference:

Benedetto Grimaldi, Marina Maria Bellet, Sayako Katada, Giuseppe Astarita, Jun Hirayama, Rajesh H. Amin, James G. Granneman, Daniele Piomelli, Todd Leff, Paolo Sassone-Corsi. PER2 Controls Lipid Metabolism by Direct Regulation of PPARγ. Cell Metabolism, Volume 12, Issue 5, 3 November 2010, Pages 509-520 DOI: 10.1016/j.cmet.2010.10.005 |

Note: If no author is given, the source is cited instead.

View the original article here

New role for master regulator in cell metabolism, response to stress: Clinical implications for obesity, diabetes and cancer research

ScienceDaily (Oct. 6, 2010) ? AMP-activated protein kinase, or AMPK, is a master regulator protein of metabolism that is conserved from yeast to humans. When a cell is low on fuel, AMPK shuts down processes that use energy and turns on processes that produce energy.

Biologists have been studying how AMPK works for several decades and know that once it is activated, AMPK turns on a large number of genes by passing the "make more energy" message through numerous signaling cascades in the cell. What was not known, until now, was that AMPK also works via an epigenetic mechanism to slow down or stop cell growth.

Shelley Berger, PhD, Daniel S. Och University Professor and director of the Epigenetics Program at the University of Pennsylvania, and David Bungard, PhD, a postdoctoral fellow in the Berger lab at the University of Pennsylvania School of Medicine, in collaboration with Craig Thompson, MD, director of the Abramson Cancer Center at Penn, and Russell G. Jones, PhD, Goodman Cancer Centre at McGill University, found that AMPK binds directly to sites on chromosomes called promoters that regulate gene expression related to cell metabolism.

They published their findings online in Science Express.

Unlike genetic changes, which involve a change or mutation in DNA sequence, epigenetic changes in the nucleus leave the DNA sequence unaltered but modify the histone proteins, which comprise the backbone of the chromosome. Histones are proteins found in the nucleus that package and order DNA into structural units. Epigentic changes alter how DNA folds in chromosomes, changing how accessible genes are to regulatory proteins and enzymes that copy genes into RNA messages.

"Epigenetics is the study of how factors outside of actual DNA interact with, but not alter, genes. It is turning out, through recent discoveries, that epigenetic information plays an important role in human health and disease," says Berger.

"Our results show a direct link between the energy state of the cell and its epigenetic status," adds Bungard.

Thus far, the investigators have identified two genes that are regulated by AMPK at the histone level in the nucleus. These initial observations were made in tissue-culture cells and the team is now working to confirm them in animal models.

AMPK's main role is to sense cell stress. In this study, cells were stressed with ultraviolet radiation and low levels of glucose, a common source of cell energy. In the sequence of events after stress, AMPK picks up the cell-stress signal and travels to the nucleus to bind to the important tumor suppressor p53 protein. This in turn, causes a phosphate to be added to a histone near the p21 gene, which turns the gene on. The function of p21 is to stop or slow down the cell cycle until energy levels are restored to normal.

The same mechanism occurs at other genes regulated by AMPK, allowing direct control of the many processes that AMPK regulates. These processes, such as sugar storage, insulin production, and other pathways, are altered in obesity and diabetes.

The researchers were surprised by these findings on many fronts: This is the first time that investigators have shown that AMPK is present on chromatin, that it targets histones, and that p53 is involved in sensing stress via AMPK. Other stress-response proteins could use similar epigenetic pathways, and thus may be a common way that cells respond to stress.

The work conducted by the team holds out promise for new therapies for a number of diseases, including diabetes and cancer. For example, AMPK is a target of metformin, the most commonly prescribed drug for the treatment of Type II diabetes. Understanding how AMPK can directly change gene expression may lead to the identification of new disease-associated targets and potential therapies.

Editor's Note: This article is not intended to provide medical advice, diagnosis or treatment.

Story Source:

The above story is reprinted (with editorial adaptations by ScienceDaily staff) from materials provided by University of Pennsylvania School of Medicine.

Journal Reference:

David Bungard, Benjamin J. Fuerth, Ping Y. Zeng, Brandon Faubert, Nancy L. Mass, Benoit Viollet, David Carling, Craig B. Thompson, Russell G. Jones, and Shelley L. Berger. Signaling Kinase AMPK Activates Stress-Promoted Transcription via Histone H2B Phosphorylation. Science, 2010; DOI: 10.1126/science.1191241

Note: If no author is given, the source is cited instead.

View the original article here